Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis

Li, Zhengrong; Zhan, Wenbin; Zhao, Wei; Zhu, Bin; He, Yulong; Peng, Junsheng; Cai, Shirong; Ma, Jingfei

doi:10.1016/j.bbrc.2006.07.043

Cited by 90 publications

(61 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 We performed intraperitoneal inoculation of cancer cells into nude mice as a model of peritoneal dissemination of the tumor, as also reported by others. 28,29 Although many gastric cancer cell lines do not show typical histological appearance of human scirrhous carcinoma when inoculated into nude mice, our system of orthotopic transplantation of 44As3 cells is a highly reproducible animal model of peritoneal dissemination of human scir- 18,19,30 Because early clinical diagnosis of scirrhous gastric carcinoma is difficult, peritoneal dissemination or metastasis to lymph nodes has frequently occurred by the time the diagnosis is made. We observed that expression of ephrin-B1 4YF suppressed not only local invasion of 44As3 cells in the gastric wall but also the infiltration of cancer cells into lymphatic vessels and lymph node metastasis.…”

Section: Discussionmentioning

confidence: 99%

Phosphorylation of Ephrin-B1 Regulates Dissemination of Gastric Scirrhous Carcinoma

Tanaka¹,

Kamata²,

Takigahira³

et al. 2007

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Phosphorylation of Ephrin-B1 Regulates Dissemination of Gastric Scirrhous Carcinoma

Tanaka¹,

Kamata²,

Takigahira³

et al. 2007

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Wang et al [21] found that the high expression of PRL-3 in lymph node metastases had a negative impact on the prognosis of patients with GC. Li et al [22][23] reported that PRL-3 expression was correlated with peritoneal metastasis and poor prognosis in GC patients. The superiority of our study may be the use of antibody specifically against PRL-3 and the relatively extensive clinical data which facilitated the analysis from multiple angels.…”

Section: Dai N Et Al Prl-3 Predict Prognosis In Gastric Cancermentioning

confidence: 99%

“…PRL-3 was further demonstrated to be a useful indicator for tumor recurrence and patient outcome in several human cancers including colorectal cancer and breast cancer [16][17][18][19] . In gastric cancer, PRL-3 was found to be highly expressed in tumor metastatic lymph nodes and closely associated with the peritoneal metastasis [20][21][22][23] , but the prognostic impact of PRL-3 expression in gastric cancer still remains to be further investigated.…”

Section: Introductionmentioning

confidence: 99%

Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer

Nakamura¹,

Lü²,

Shou³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate the prognostic significance of phosphatase regenerating liver 3 (PRL-3) protein expression in gastric cancer. METHODS:PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Monoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique. RESULTS:Positive PRL-3 expression was detected in 43.3% (127 of 293) of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression (28.3% vs 51.9%, P < 0.0001). Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression (hazard ratio of 16.7 and 16.6, respectively; P < 0.0001 for both).Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage Ⅲ patients.CONCLUSION: PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.

show abstract

“…Introduction of Pol II-mediated, artificial intronic miRNA system against b-catenin or noggin into chicken embryos resulted in long-term (41 month) silencing of the specific gene and a correspondingly altered phenotype. 29 With the use of a plasmid-driven artificial miRNA based on the the murine miR-155 sequence, Li and co-workers 124 demonstrated the in vivo silencing of PRL-3, a protein tyrosine phosphatase, resulting in growth suppression of peritoneal metastases and improved survival of nude mice bearing gastric carcinoma xenografts. Conversely, miRNAs can be inhibited in vitro with specific 2 0 -O-methyl oligonucleotide antagonists (AMOs), [124][125][126] or 'antagomirs' when delivered in the form of liposomal complex into adult mice, 56 and conceivably can be used to negate the translational-regulatory effects of 'oncogenic' miRNAs.…”

mentioning

confidence: 99%

Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

2008

View full text Add to dashboard Cite

MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (B22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell growth, differentiation and apoptosis. miRNAs are multispecific by nature. The individual miRNA is capable of modulating the expression of a network of mRNAs that it binds by imperfect sequence complementarity. Human cancers commonly exhibit an altered expression profile of miRNAs with oncogenic (miR-21, miR-106a and miR-155) or tumor-suppressive (let-7, miR-15a/16, miR-34a and miR-143/145) activity. As consistent with the natural function of miRNAs in specifying cellular phenotype, miRNA-based cancer gene therapy offers the theoretical appeal of targeting multiple gene networks that are controlled by a single, aberrantly expressed miRNA. Reconstitution of tumor-suppressive miRNA, or sequence-specific knockdown of oncogenic miRNAs by 'antagomirs,' has produced favorable antitumor outcomes in experimental models. We discuss pending issues that need to be resolved prior to the consideration of miRNA-based experimental cancer gene therapy. These include the need for definitive mRNA target validation, our incomplete understanding of rate-limiting cellular components that impact the efficiency of this posttranscriptional gene-silencing phenomenon, the possibility for nonspecific immune activation and the lack of a defined, optimal mode of delivery.

show abstract

Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis

Cited by 90 publications

References 33 publications

Phosphorylation of Ephrin-B1 Regulates Dissemination of Gastric Scirrhous Carcinoma

Phosphorylation of Ephrin-B1 Regulates Dissemination of Gastric Scirrhous Carcinoma

Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer

Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

Contact Info

Product

Resources

About